China Launches Breast Biopsy Needle Pool Procurement, Domestic Giants Such as Xishan Technology Lead the Way, and It May Reshape the Industry Landscape in 5 Years

Recently, several regions, including Sichuan, Shanxi, and Inner Mongolia, have launched data reporting for breast biopsy needle medical consumables, marking the rapid advancement of national joint procurement in this medical consumable field. This move is an important opportunity for China's medical consumable industry. For a long time, the breast biopsy needle medical consumable market has been dominated by multinational enterprises, but with the continuous improvement of Chinese enterprises' technical level, they are gradually gaining a larger market share. The Chinese brand Xishan Science and Technology is emerging as an example, and the breast lesion rotary cutting biopsy system developed by them is the first Chinese brand product to achieve industrialization.

Industry insiders believe that under the push of China's national joint procurement, more high-quality Chinese products are expected to enter clinical application, further changing the industry landscape. This not only benefits patients by reducing their economic burden, but also provides vast development space for Chinese manufacturers. At the same time, it reflects that China's medical consumable market is undergoing profound changes. With the National Medical Insurance Administration's intensive push for national joint procurement of various medical consumables, from vascular tissue closure hemostatic clamp to biochemical in vitro diagnostic reagents, a series of procurement activities in various medical consumable fields are being rolled out one after another. This not only helps adjust the industry competitive landscape, but also further improves the quality and efficiency of medical services, bringing tangible benefits to patients.

As Chinese medical consumable manufacturers' technical level continues to improve and the national joint procurement deepens, more and more high-quality Chinese products are expected to enter clinical application, allowing "China-made" to make an even louder voice in the medical field. This not only enhances the international competitiveness of Chinese-made medical consumables, but also brings more choices and better treatment outcomes for patients.